Actively Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Led by Contineum Therapeutics · Updated on 2026-02-04
324
Participants Needed
2
Research Sites
125 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
CONDITIONS
Official Title
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female 40 years of age or older at the time of randomization
- Diagnosis of Idiopathic Pulmonary Fibrosis within 7 years prior to screening confirmed by investigator and HRCT
- Percent predicted forced vital capacity (FVC) 40% or higher on screening spirometry
- May be receiving background antifibrotic therapy (nintedanib or pirfenidone, but not both concurrently)
You will not qualify if you...
- History of interstitial lung disease other than Idiopathic Pulmonary Fibrosis
- Pulmonary arterial hypertension requiring multi-drug therapy
- Experienced an IPF exacerbation within 6 weeks before or during screening
- Estimated glomerular filtration rate (eGFR) 30 ml/min/1.73 m2 or lower
- Child-Pugh Class B or C hepatic impairment
- Additional unspecified exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Dynamic Drug Advancement Ltd.
Ajax, Ontario, Canada, L1S 2J5
Actively Recruiting
2
Dr. Anil Dhar Medicine Professional Corporation
Windsor, Ontario, Canada, N8X 5A6
Actively Recruiting
Research Team
N
Nikki Nepomuceno
CONTACT
M
Marietta Franco
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here